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Running title: HLSC-EVs inhibit tumor angiogenesis 
Abstract 
Human liver stem-like cells (HLSC) and derived extracellular vesicles (EVs) were 
previously shown to exhibit anti-tumor activity. In the present study, we investigated 
whether HLSC-derived EVs (HLSC-EVs) were able to inhibit tumor angiogenesis in vitro 
and in vivo, in comparison with EVs derived from mesenchymal stem cells (MSC-EVs). The 
results obtained indicated that HLSC-EVs but not MSC-EVs inhibited the angiogenic 
properties of tumor-derived endothelial cells (TEC) both in vitro and in vivo in a model of 
subcutaneous implantation in Matrigel. Treatment of TEC with HLSC-EVs led to the down-
regulation of pro-angiogenic genes. Since HLSC-EVs carry a specific set of microRNAs 
(miRNAs) that could target these genes, we investigated their potential role by transfecting 
TEC with HLSC-EV specific miRNAs. We observed that four miRNAs, namely miR-15a, 
miR-181b, miR-320c, and miR-874, significantly inhibited the angiogenic properties of TEC 
in vitro, and decreased the expression of their target genes (ITGB3, FGF1, EPHB4, PLAU). 
In parallel, TEC treated with HLSC-EVs significantly enhanced expression of miR-15a, 
miR-181b, miR-320c, and miR-874 associated with the down-regulation of FGF1 and 
PLAU. In summary, HLSC-EVs possess an anti-tumorigenic effect, based on their ability to 
inhibit tumor angiogenesis. 
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INTRODUCTION 
Tumor vascularization is a fundamental step in tumor growth and metastasis. Solid tumors are in 
fact unable to grow more than a few millimetres per square in the absence of a vascular supply of 
oxygen and nutrients. Moreover, the number of metastases was reported to correlate with the 
vessel density of the primary tumor 1. Tumor endothelial cells (TEC) are distinct from normal 
endothelial cells and display a pro-angiogenic phenotype 2, 3. For instance, TEC demonstrate a 
higher in vitro motility and proliferation independent from serum and enhanced survival through 
Akt signaling 4. From a phenotypic point of view, TEC have an altered expression of growth 
factors and their receptors, including VEGF and EGF receptors 5, integrins 6, 7, and extracellular 
matrix proteins 8. TEC are also resistant to chemotherapeutic drugs and less sensitive to anti-
angiogenic drugs targeting VEGF 9-11. Furthermore, TEC genetically differ from normal 
endothelial cells 12-14.  
Extracellular vesicles (EVs) are an important mechanism for cell-to-cell communication, and their 
active cargo may reprogram recipient cells, modifying their function and phenotype 15. In fact, the 
activity of EVs seems to rely on the transfer of a number of different factors, including proteins, 
RNA, DNA, and lipids 16-18. Stem cell-derived EVs and in particular human bone marrow-derived 
mesenchymal stromal cells (MSC) have been shown to display both pro-tumorigenic and anti-
tumorigenic activities, depending on the tumor type and stage of development. In analogy, MSC-
EVs may also modulate tumor vascularization in a positive or negative manner. For instance, 
MSC-EVs were reported to be pro-angiogenic after in vivo administration into tumor-bearing mice 
19, 20. Other studies 21-23 detected an indirect inhibitory effect of MSC-EVs on VEGF secretion by 
tumor cells. The mechanisms of this inhibition have been suggested to be due to the VEGF-
targeting effect of miR-16 21 and the down-regulation of PDGF/PDGFR axis 22.  
Recently, we showed that the human liver stem-like cells (HLSC), another source of human 
resident mesenchymal stromal cells isolated from the liver 24, may display anti-tumor effects. In 
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particular, HLSC-EVs decreased the growth and survival of a number of different tumors, such as 
hepatocellular carcinoma, lymphoblastoma and glioblastoma 25. 
In this study, we aimed to investigate the effect of MSC-EVs and HLSC-EVs on TEC isolated 
from renal carcinomas. In addition, we analyzed the potential role of microRNAs (miRNAs), 
carried by EVs in their biological activity.  
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RESULTS 
HLSC-EVs inhibit the angiogenic potential and migration of renal TEC in vitro. 
Stimulation with HLSC-EVs significantly inhibited the angiogenic properties of human renal TEC 
in vitro in a dose-depended manner (Figure 1, A, B, D). At variance, MSC-EVs did not show pro- 
or anti-angiogenic effects on TEC (Figure 1, A, C, D). Both EVs did not change TEC viability 
(data not shown). We also evaluated the effect of MSC-EVs and HLSC-EVs on the motility of 
TEC through a wound-healing assay. Both EVs significantly inhibited the migration of TEC at the 
dose of 10×103 EVs per TEC. However, HLSC-EVs were already effective at the lower dose of 
1×103 EVs per TEC (Figure 1, E) compared to MSC-EVs.  
As control experiments, we evaluated the effect of MSC-EVs and HLSC-EVs on normal 
endothelial cells: MSC-EVs were able to enhance the angiogenic property of human microvascular 
endothelial cells (HMECs), in line with their reported pro-angiogenic activity 26, whereas HLSC-
EVs did not show any effect (Figure 1, F). This indicates that EVs from MSC and HLSC have 
different action on normal and tumor angiogenesis.  
HLSC-EVs prevent tumor angiogenesis in vivo. 
We subsequently evaluated the effect of MSC-EVs and HLSC-EVs in vivo by using a model of 
human tumor angiogenesis induced by TEC implanted subcutaneously in SCID mice within 
Matrigel 4. In this model, TEC organize in patent structures connected with the mouse circulation 
within 7 days. In a pre-treatment setting, TEC were incubated with HLSC-EVs or MSC-EVs for 24 
hours and implanted subcutaneously into SCID mice. Seven days after implantation, Matrigel 
plugs were excised and vessel density analyzed by trichrome staining. The analysis of control 
plugs showed, as expected, the presence of erythrocyte containing vessels (Figure 2, A). Plugs of 
TEC treated with HLSC-EVs for 24 hours before implantation did not present vessels (Figure 2 B, 
D), whereas those treated with MSC-EVs were highly angiogenic (Figure 2 C, D).  
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To evaluate whether EVs were able to affect formed tumor vessels, HLSC-EVs or MSC-EVs were 
injected at day 3 and 7 in Matrigel plugs containing an established TEC network. Plugs were 
explanted at day 10. The treatment with HLSC-EVs significantly reduced vessel density with 
respect to control and to treatment with MSC-EVs (Figure 2, E), confirming the in vitro results.  
Molecular effects of HLSC-EVs on TEC 
Based on these results, a molecular analysis of the changes occurring in TEC after HLSC-EVs 
stimulation during in vitro vessel-like structure organization was conducted using an Angiogenesis 
PCR array. Briefly, TEC were treated with HLSC-EVs (10×103 EVs/TEC) during in vitro 
angiogenesis and subsequently harvested for the PCR array. Among the 84 genes tested, we 
identified 11 pro-angiogenic factors significantly down-regulated in TEC treated with HLSC-EVs 
in vitro (Figure 3, A). In particular, HLSC-EVs down-regulated pro-angiogenic surface receptors 
including Tie-1, beta 3 integrin (ITGB3), ephrin receptor B4 (EPHB4) and endoglin (or CD105), 
as well as growth factors such as fibroblast growth factor 1 (FGF1), TGF family members, 
urokinase-type plasminogen activator (PLAU) and tissue factor (F3). Additionally, Akt1, known to 
be involved in the pro-angiogenic effects of TEC 27, was also down-regulated.  
Identification of anti-angiogenic miRNAs carried by HLSC-EVs  
To dissect the possible effectors of the observed gene regulation, we focused on miRNA content of 
HLSC-EVs. In order to accomplish this, we performed a bioinformatic analysis, followed by in 
vitro functional validation. 
Using Funrich V3 software 28, we predicted miRNAs that target the 11 down-regulated genes. We 
identified 136 miRNAs and we matched them with miRNAs carried by HLSC-EVs. Among them, 
we identified 42 miRNAs expressed by HLSC-EVs (Figure 3, B). A subsequent analysis was 
performed to exclude those also present in MSC-EVs 29, due to their lacking effect on TEC (Figure 
3, C). The complete list of HLSC- and MSC-EV microRNAs can be found in the exocarta 
repository (http://exocarta.org, number under request). Sixteen out of 42 miRNAs targeting the 
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identified genes were identified to be present only in HLSC-EVs and were adopted for further 
functional studies (Figure 3, D). Among them, three described as pro-tumorigenic (has-miR-30e-
5p, has-miR-301a-3p, has-miR-212-3p) 30-32 were excluded. Therefore, we took in consideration 8 
miRNAs: miR-15a, miR-20b, miR-23a, miR-93, miR-181b, miR-320c, miR-424, and miR-874 
(Figure 3, D, in bold). Of importance, these selected miRNAs were expressed in low-level in the 
control TEC (Ct>33).  
Effect of HLSC-EV miRNAs on TEC angiogenesis 
To demonstrate the specificity of these selected miRNAs on the angiogenic properties of TEC, we 
transfected cells with the corresponding miRNA mimics. Two days after transfection, angiogenesis 
in vitro assay was performed. Four miRNAs (miR-15a, miR-181b, miR-320c and miR-874) 
significantly inhibited in vitro vessel-like structure formation (Figure 4, A), whereas miR-20b, 
miR-23a, miR-93, and miR-424 had no effect. Furthermore, all mimics had no effect on 
proliferation or apoptosis (Figure 4, B and C).  
The next step was to investigate changes in the predicted targets’ expression induced by the 
transfection with the four active miRNA mimics. The results showed a significant down-regulation 
of EPHB4, ITGB3, FGF1, and PLAU (Table 1, Figure 5).  
 In parallel, we evaluated the effective transfer of these miRNAs by HLSC-EVs in TEC. After 24 h 
incubation, these miRNAs, that had low basal expression in untreated cells, were significantly up-
regulated (Figure 6, A), therefore validating ours in silico data. In parallel, we evaluated the effect 
of HLSC-EVs on the four genes found to be targets of the mimics (EPHB4, ITGB3, FGF1, and 
PLAU). We confirmed at both mRNA and protein level the down-regulation of FGF1 and PLAU 
in TEC treated with HLSC-EVs (Figure 6, B, C, and D).  
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DISCUSSION 
In the present study, we found that EVs from a stromal stem cell population obtained from the 
human liver inhibited migration of tumor endothelial cells, and significantly reduced vessel-like 
formation in vitro. Experiments performed in vivo in a model of tumor angiogenesis in SCID mice 
also showed that HLSC-EVs were able to inhibit vessel formation and growth. This effect 
appeared to be specific to HLSC-EVs as bone marrow-derived MSC-EVs did not display any 
effect. In addition, this anti-angiogenic feature of HLSC-EVs was dependent on the presence of a 
specific miRNA subset. 
Tumor angiogenesis has different characteristics and mechanisms in respect to normal 
angiogenesis. TEC derived from renal carcinoma were shown to be able to form in vivo a human 
vascular network connected with mouse vasculature once implanted within Matrigel in mice 2, 4. 
These cells maintain a pro-angiogenic program in an autocrine manner 2, 4. Several studies have 
previously shown that endothelial cells derived from different tumors are different from the normal 
endothelium as they express a distinct and unique molecular and functional phenotype 2, 33. EVs 
released from stem cells were shown to be able to reprogram target cells by inducing epigenetic 
changes 34, 35. This observation prompted us to investigate whether EVs derived from MSC and 
HLSC were able to modify the pro-angiogenic phenotype of TEC.  
Previous studies of the effect of MSC and MSC-derived EVs provided conflicting results on in 
vivo tumor growth 19, 21, 36. These contradictory results probably depend on cell growth conditions 
and on timing of administration 37-39. MSC-EVs are described as strictly pro-angiogenic for healthy 
endothelial cells 40, 41. Lindoso et al. showed that EVs derived from MSC primed by tumor cells 
acquired a pro-angiogenic and pro-tumorigenic activity 42. In the present study, we found that 
MSC-EVs were able to inhibit migration but not influence proliferation and angiogenesis of TEC. 
Pre-treatment of TEC with MSC-EVs was unable to modify the formation of an in vivo vascular 
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network by TEC. In contrast to MSC-EVs, HLSC-EVs were found to possess an intrinsic anti-
angiogenic activity. Previous studies have shown that HLSC-EVs inhibited tumor growth both in 
vitro and in vivo and the mechanism was related to the delivery of anti-tumor miRNAs that were 
able to down-regulate oncogenic targets 25. Herein, we have found that HLSC-EVs were able to 
almost completely abrogate tumor angiogenesis in vitro and in vivo without affecting normal 
endothelial cells.  
EVs are complex structures composed of specific functional proteins, lipids, and nucleic acids. The 
biological activity of EVs depends on the coordinated action of all these components. However, a 
number of reports have indicated the relevant role of EV mediated miRNA transfer in inducing 
epigenetic changes in target cells. In the present study, we identified four miRNAs carried by 
HLSC-EVs but not by MSC-EVs with an anti-angiogenic function. These miRNAs, miR-15a, mir-
181b, miR-320c, and miR-874, were able to inhibit tumor angiogenesis when transfected in TEC 
mainly by down-regulating the expression of their target genes (FGF1, PLAU, ITGB3, and 
EPHB4). In parallel, when TEC were stimulated with HLSC-EVs, a significantly enhanced 
expression of these miRNAs was observed. The effective down-regulation of the predicted target 
genes was observed only for FGF1 and PLAU. These miRNAs were previously described to have 
different function in tumors. MiR-15a is a well-known tumor suppressor. This miRNA inhibits cell 
proliferation, promotes apoptosis of cancer cells, and suppresses tumor growth by targeting 
multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A 43. MiR-181b could play a 
contradictory role in tumor development depending on the type of tumor and cell being studied 44. 
Mir-874 is described not only as a tumor suppressor 45-47 but also as an inhibitor of tumor 
angiogenesis through STAT3/VEGF-A pathway 48. miR-320c, on the other hand, has been shown 
to be down-regulated in many types of cancer, such as myeloma 49, colorectal cancer 50, and 
bladder cancer 51. Predicted targets that we have found by the Funrich online software for every 
miRNA have not been previously described or confirmed, except for EPHB4 as a target for miR-
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181 52. After the transfection of TEC with the selected miRNAs or stimulation with HLSC-EVs, 
two predicted pro-angiogenic genes were significantly down-regulated at mRNA and protein level. 
FGF1 is one of the most important pro-angiogenic factor involved in tumor angiogenesis 53, 54. 
FGF1 is able to regulate angiogenesis independently from VEGF 55 and an enhanced expression of 
this factor has been reported in different types of tumors 56, 57. PLAU is a gene that codes for 
urokinase-type plasminogen activator (uPA), an enzyme that activates plasmin from plasminogen. 
Plasmin participates in the proteolytic processes of extracellular matrix degradation which is 
important for angiogenesis and cancer progression 58. FGF1 and PLAU are connected through the 
receptors of FGF1 (FGFRs) that could activate uPA and enhance the expression of its receptor 
uPAR. Furthermore, FGF1, uPA, and uPAR are all linked through FGFRs creating a positive 
feedback loop. In fact, cells overexpressing FGFRs were shown to be more invasive and 
tumorigenic 59.  
In conclusion, we have shown that HLSC-EVs specifically and significantly inhibit tumor 
angiogenesis in vitro and in vivo. Furthermore, based on the bioinformatic analysis and the 
characterization of anti-angiogenic miRNAs carried by HLSC-EVs, we postulate that EV mediated 
transfer of miRNAs may be involved in the inhibition of tumor angiogenesis through down-
regulation of a number of genes including FGF1 and PLAU.  
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MATERIALS AND METHODS 
Cell cultures 
TEC have been previously isolated and cultured in our laboratory from surgical specimens of 
patients with renal carcinomas 4. TEC were isolated from digested tissue using anti-CD105 
positive selection by magnetic cell sorting (MACS system, Miltenyi Biotech) and grown in 
EndoGro complete medium (Millipore), as described previously 4.  
HLSC were isolated in our laboratory from human cryopreserved normal hepatocytes obtained 
from Lonza as described previously 24. Briefly, cells were plated in hepatocyte serum-free medium 
(Gibco Hepatozyme-SFM; Invitrogen) at a density of 1.0–1.5×105 viable cells per cm2 on 
collagen-coated culture plates for 2 weeks. After 2 weeks of culture, the medium was substituted to 
α -minimum essential medium/endothelial cell basal medium-1 (α-MEM/EBM) (3:1) 
(Gibco/Euroclone) supplemented with L-glutamine (5 mM), Hepes (12 mM, pH7.4), penicillin (50 
IU/ml), streptomycin (50 μg/ml), (all from Sigma), and 10 % FBS (Lonza). At this moment, 
individually attached cells were cloned after 3 weeks and expanded. HLSC were positive for 
CD73, CD90, CD29, and CD44 and negative for CD45, CD34, CD117 (c-kit), and CD133. 
MSC were purchased from Lonza and cultured in MSCBM complete medium (Lonza). 
EV isolation and characterization 
Isolation of EVs was performed as described previously 60 with minor modifications. Briefly, 
confluent HLSC or MSC were cultured in serum-free RPMI FBS free for 18 hours. Post culture, 
the medium was centrifuged for 30 minutes at 3000g to remove cell debris and apoptotic bodies. 
After which, the supernatant was ultracentrifuged for 2 hours at 100.000g, 4°C using the Beckman 
Coulter Optima L-100K Ultracentrifuge with the rotor type 45 Ti 45000RPM. The pellet of EVs 
obtained was resuspended in RPMI supplemented with 10 % of DMSO. Suspension of HLSC-EVs 
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was then stored at -80°C until further use. EVs were analyzed using NTA analysis and electron 
microscopy. Mean size of EVs was 90 nm (± 20) (Supplementary figure).  
Viability and migration tests  
For the proliferation test, TEC were seeded in a 96 well plate at the density of 2×103/well. The 
next day, cells were treated with HLSC-EVs or MSC-EVs at the concentrations of 1×103, or 5×103, 
or 10×103 EVs per TEC in EndoGro complete medium (Lonza). Proliferation was measured by 
BrdU incorporation at 24, 48 and 72 hours post EVs stimulation using Cell Proliferation ELISA, 
BrdU (colorimetric) kit (Roche, 11647229001) according to the manufacturer’s instructions. For 
the migration test, TEC were seeded in a 24-well plate and grown to confluence. EVs were then 
added in the concentrations of 1×1015, or 5×1015, or 10×1015 EVs/well just after the scratch was 
done. Images were captured using a light microscope with the magnification of 10× at the time 
points of 0, 3, 7 and 24 hours after the scratch. The distance was measured by LAS software 
(Leica) and, the results expressed as mean ± SEM of three independent experiments. 
Vessel-like structure formation in vitro 
TEC were seeded onto Matrigel-coated 24-well plates at the density of 25×103 cells per well and 
cultured in EndoGro complete medium in the presence of 1×103, 5×103, 10×103 or 20×103 EVs per 
TEC. TEC without EVs served as a control. After incubating for 24 h, phase-contrast images 
(magnification, 10×) were recorded and the total length of the network structures was measured 
using LAS software (Leica). The total length per field was calculated in five random fields and 
expressed as a ratio respective to the control. Data were expressed as mean ± SEM. 
In vivo angiogenesis model 
Animal studies were conducted in accordance with the national guidelines and regulations and 
were approved by the Ethics Committee of the University of Torino (Protocol Number: 338/2016-
PR). A model of in vivo tumor angiogenesis obtained by TEC the injection of Matrigel 
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incorporated with TEC was used to assess the effect of stem cell-derived EVs, as described 
previously 4. To prevent the development of tumor angiogenesis TEC were pre-treated before 
injecting. For this purpose SCID mice (6-8 weeks old) (Charles River Laboratories) were 
subcutaneously injected with 1×106 TEC incorporated within Matrigel, pre-treated or not with 
HLSC-EVs/MSC-EVs (10×103 EV per cell): (n=8 each group). After 7 days, Matrigel plugs were 
excised and vessel density was analyzed by Masson’s trichromic reaction staining. To evaluate the 
influence of EVs on established tumor vessels, Matrigel incorporated with 1×106 TEC was 
subcutaneously injected in SCID mice. HLSC-EVs or MSC-EVs (10×103 EVs per cell or 1×1010 
EVs per plug) were injected twice into Matrigel plugs on day 3 and 7 post injection. Control mice 
were injected with the vehicle (PBS). At day 10 of the experiment, mice were sacrificed and 
Matrigel plugs excised for histochemical analysis (n=8 for each group).  
Gene expression study and Real-time PCR 
miRNA expression levels in HLSC-EVs or MSC-EVs were evaluated using the Applied 
Biosystems TaqMan® Array Human MicroRNA A/B Cards (Applied Biosystems, Foster City, 
CA) to profile 754 mature miRNAs by qRT-PCR. The kit used miRNA-specific stem-loop reverse 
transcription primers and TaqMan probes to detect mature miRNA transcripts in a 2-step real-time 
reverse-transcription PCR assay. Briefly, single-stranded cDNA was generated from total RNA 
sample (80 ng) by reverse transcription using a mixture of looped primers (Multiplex RT kit, 
Applied Biosystems) following the manufacturer's protocol. The RT reactions were then diluted 
and mixed with a Taqman universal master Mix (Applied) in a ratio of 1:1, and loaded in the 
TaqMan microfluid card to analyze via qRT-PCR. All reactions were performed using an Applied 
Biosystems 7900HT real-time PCR instrument equipped with a 384 well reaction plate. Raw Ct 
values were calculated using the SDS software version 2.3 using automatic baseline and threshold. 
We analyzed the expression of miRNAs in 3 replicate samples of HLSC-EVs. All miRNAs that 
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were amplified after 35 cycles of PCR were classified as unexpressed. Furthermore, only miRNAs 
that were detected or undetected in more than two replicate samples were taken into consideration.  
qRT-PCR was used to confirm miRNAs or target gene expression in TEC. Briefly, 200 ng of input 
RNA from all samples were reverse transcribed with the miScript Reverse Transcription Kit and 
the cDNA was then used to detect and quantify miRNAs or genes of interest by qRT-PCR using 
the miScript SYBR Green PCR Kit (all from Qiagen). All samples were run in triplicate using 3 ng 
of cDNA for each reaction as described by the manufacturer's protocol (Qiagen). Relative 
expression data were then normalized using the mean expression value, calculated on the overall 
miRNA expression in each array, according to a Ct detection cut-off of 35 PCR cycles as described 
by Mestdagh et al. 61. 
PCR analysis of the expression of pro-angiogenic genes in TEC, treated or not with HLSC-EVs, 
was done using Human Angiogenesis PCR Array (RT2 Profiler PCR array, 96/well Format, 
Qiagen) in triplicate according to the manufacturers’ instructions. Data were analyzed using 
SaBioscience (Qiagen) online software and expressed as Relative Quantification ± CI (Confidence 
interval). To compare the list of genes down-regulated in TEC after HLSC-EVs stimulation 
(miRNAs carried by these EVs) the online software FunRich (http://funrich.org) was used.  
Cell transfection 
Transfection of TEC was performed using HiPerfect reagent (Qiagen). To identify the optimal 
concentration for transfection, TEC were transfected with a scramble control RNA marked with 
FITC. FACS analysis performed the day after transfection, revealed that more than 60 % of TEC 
were transfected with no damage on their viability and proliferation.  
Transfection of TEC was performed using the following mimic miRNAs: miR-15a, miR-20b, 
miR-23a, miR-93, miR-181b, miR-320c, miR-424, and miR-874 (all from Qiagen). The day after 
transfection fresh growth medium was replaced and at day two the cells were used for in vitro 
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experiments (proliferation, apoptosis tests, angiogenesis in vitro assay) or gene expression analysis 
(Real-time PCR, Western blot, FACS analysis).  
Fluorescence-activated cell sorting (FACS) analysis 
FACS analysis of HLSC-EVs and MSC-EVs was performed using CytoFLEX Flow Cytometer 
(Beckman Coulter) (Supplementary figure). Antibodies used were: the FITC- conjugated 
antibodies anti CD63 (Abnova), anti CD105 (Dako Cytomation), anti CD90 (BD Pharmigen), anti 
CD44 (Miltenyi Biotech), CD45 (BD Pharmigen), anti ICAM and anti VCAM (Serotec), CD31 
(BioLegend), integrin subunit α4, α5, α6 (from BD Pharmigen); PE- conjugated antibodies anti 
CD73 (BD Pharmigen), anti integrin subunit α4, α5 (all from BD Pharmigen) and VE-cadherin 
(BioLegend). FITC or PE mouse non-immune isotypic IgG (Dako Cytomation) were used as a 
control. 
Western blot 
Protein samples were separated by 4% to 15% gradient sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis (SDS PAGE) and subjected to immunoblotting with antibodies to PLAU 
(Abcam, ab131433) or FGF1 (Abcam ab9588). The protein bands were visualized with an 
enhanced chemiluminescence detection kit and ChemiDoc™ XRS+ System (BioRad). Cell lysates 
(20 μg protein) were loaded per well. 
Statistics 
Data were assessed for normality of distribution using the Kolmogorov-Smirnov test. Statistical 
analysis was performed using SigmaPlot 11.0 Software. Differences between treatment and control 
groups were then analyzed using Dunnett's test when the distribution was normal. Data are 
expressed as mean ± SEM. We considered differences to be significant when p<0.05. 
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Table 1. Relative expression of pro-angiogenic genes in TEC, transfected with selected miRNAs, 
versus control TEC; in brackets, miRNAs that target the demonstrated genes.  
Gene 
RQ in transfected TEC 
vs. control TEC 
Targeting miRNA 
ITGB3 0.33 miR-320c 
FGF1 0.39 miR-15a 
EPHB4 
0.39 
0.48 
miR-181b 
miR-874 
PLAU 0.51 miR-181b 
  22
Figure legends: 
 
Figure 1. The effect of HLSC-EVs or MSC-EVs on the angiogenic properties of TEC in vitro. 
Formation of vessel-like structures by control TEC (A), by TEC treated with HLSC-EVs (B) or 
with MSC-EVs (C); (D) diagram of the total length of vessel-like structures per field, formed by 
control TEC or TEC treated with different doses of EVs; (E) diagram of the TEC migration during 
wound healing assay in the presence or absence of different doses of EVs; (F) diagram of the total 
length of vessel-like structures per field, formed by HMEC, treated with different doses of EVs. 
Data are expressed as mean ± SEM of 3 experiments performed in duplicate. Statistical analysis 
was performed using Dunnett's test vs. control stimulated with vehicle alone. * - p<0.05. 
 
Figure 2. Tumor angiogenesis in vivo. Representative images of Matrigel sections, stained with 
Masson’s trichromic reaction (extracellular matrix is stained in blue, cells in red and erythrocytes 
in yellow): (A) Matrigel plugs containing control TEC treated with vehicle alone; (B) Matrigel 
plugs containing TEC, pre-treated with 10×103 HLSC-EVs per cell; (C) Matrigel plugs containing 
TEC, pre-treated with 10×103 MSC-EVs per cell. (Original magnification ×20; erythrocytes 
containing vessels are indicated by arrows). (D) Diagram of vessel density in Matrigel containing 
control TEC or TEC pre-treated with HLSC-EVs or MSC-EVs. (E) Diagram of vessel density in 
TEC contained Matrigel, injected or not with HLSC-EVs or MSC-EVs on day 3 and 7 after TEC 
injection. Data are expressed as mean ± SEM of 8 experiments performed independently. 
Statistical analysis was performed using Dunnett's test vs. control group stimulated with vehicle 
alone. * - p<0.05; ***- p<0.001. 
 
Figure 3. Selection of miRNAs specific to HLSC-EVs responsible for the anti-angiogenic 
effect on TEC. (A) List of the genes down-regulated in TEC after treatment with HLSC-EVs (n=3 
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experiments; data are expressed as average Fold change ± CI (Confidence interval); these genes 
could be targeted by 136 miRNAs (B), 42 of which are carried by HLSC-EVs. Among these 42 
miRNAs, 26 are also carried by MSC-EVs, which did not show any anti-angiogenic effect on 
TEC, therefore these 26 miRNAs were excluded from the study (C). Panel C shows 16 miRNAs 
specific to HLSC-EVs that could be relevant towards the biologic action of EVs on TEC. miRNAs 
selected for further studies are indicated in bold (D). 
 
Figure 4. Influence of selected miRNAs transfected in TEC on their pro-angiogenic 
properties and viability. The diagrams show: (A) in vitro vessel-like structure formation by TEC 
transfected with selected mimic RNA or scramble RNA; (B) apoptosis rate of the transfected TEC; 
(C) proliferation rate of the transfected TEC. Data are expressed as mean ± SEM of 3 experiments 
performed independently. Statistical analysis was performed using Dunnett's test vs. control 
transfected with scramble RNA. * - p<0.05. 
 
Figure 5. Expression of miRNAs and their targets in TEC, transfected with the selected 
mimic miRNAs. (A) expression of miR-15a and its target genes FGF1, EPHB4; (B) expression of 
miR-181b and its target genes PLAU, ITGB3, FGF1, EPHB4; (C) expression of miR-320c and its 
target genes PLAU, ITGB4, FGF1; (D) expression of miR-874 and its target genes EPHB4, 
PLAU, ITGB3, FGF1; Data are expressed as RQ mean ± SEM of 5 experiments performed. 
Statistical analysis was performed using Dunnett's test vs. control transfected with scramble RNA. 
* - p<0.05. 
 
Figure 6. Expression of miRNAs and their targets in TEC treated with HLSC-EVs. (A) 
Relative expression of miRNAs in the control TEC and TEC treated with HLSC-EVs; (B) Relative 
expression of target genes in control TEC and TEC treated with HLSC-EVs; (C) Representative 
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image of Western blot analysis of the FGF1 expression in control TEC, TEC transfected with miR-
15a or stimulated with HLSC-EVs. (D) Representative image of Western blots showing the 
expression of PLAU in control TEC, TEC transfected with miR-181b or stimulated with HLSC-
EVs. Data are expressed as mean ± SEM of 6 experiments performed independently. Statistical 
analysis was performed using Dunnett's test vs. control TEC treated with vehicle alone; * - p<0.05. 
 
 
Supplementary figure 1. Characterization of MSC- and HLSC-derived EVs. 
(A) Representative image of NTA analysis of HLSC-EVs; (B) representative image of NTA 
analysis of MSC-EVs; (C) Representative electron microscopy image of HLSC-EVs, 100×, (black 
line, 400 nm); (D) – Representative electron microscopy image of HLSC-EVs, 100×, (black line, 
400 nm); (E) – Surface marker expression of HLSC-EVs and MSC-EVs according to FACS 
analysis. Data are expressed as mean ± SEM of 3 experiments. 
 
 
 
 
 






